Virtual Screening for Potential Substances for the Prophylaxis of HIV Infection in Libraries of Commercially Available Organic Compounds

Lagunin, A. A.; Filimonov, D. A.; Gloriozova, T. A.; Tarasova, O. A.; Zakharov, A. V.; Guasch, L.; Nicklaus, M. C.; Poroikov, V. V.
October 2013
Pharmaceutical Chemistry Journal;Oct2013, Vol. 47 Issue 7, p343
Academic Journal
The search for new substances for the treatment and prophylaxis of HIV-AIDS remains relevant despite advances in highly active antiretroviral therapy (HAART), both because of the appearance of resistance to existing agents and because of their side effects and toxicity. Preventing the spread of HIV infection via sexual contacts by treating the uninfected partner has some advantage, as prophylactic effects can be obtained using simpler treatment (for example, using one agent rather than combinations of three drugs), as the need is to block the transfer of small numbers of infective virions. On the other hand, agents acting on the uninfected partner must be relatively nontoxic as they have to be used for long periods of time in healthy people. Effective chemoprophylaxis can be obtained using agents blocking the life cycle of the virus before integration into the human genome. Two widely used classes of agent therefore have potential – non-nucleoside reverse transcriptase (RT) inhibitors and integrase (IN) strand transfer inhibitors. In addition, proteins such as CD4, gp120, CCR5, CXCR4, and gp41 can be regarded as potential targets, as their functional roles at different stages in the interaction between virion and host cell have been established. As it is now known that all antiretroviral agents approved for medical use induce resistant viral strains, new anti-HIV agents must have chemical structures which are significantly different from known drugs and (if possible) must act on multiple pharmacological targets. Candidates can be sought by virtual screening of libraries of commercially available samples of chemical compounds; such libraries currently contain several million structural formulas for compounds which have been synthesized and are available for biological testing. Virtual screening can be performed using the computer programs PASS and PharmaExpert, allowing identification of substances with potential for experimental studies on the basis of a number of prognostic criteria (presence of the required types of activity, absence of side and toxic effects, appropriate physicochemical properties).We present here data on the current state of the search for new agents for the treatment and prophylaxis of HIV/AIDS, our approach to virtual screening for new potential substances for the prophylaxis of HIV/AIDS, and the results of using this approach in databases of chemical compounds available for screening. The potential for detection of anti-HIV compounds acting on multiple pharmacological targets among substances which have already been synthesized is discussed. We conclude that there is potential for the rational design of such drugs using computerized drug construction methods.


Related Articles

  • Daily pill can end HIV epidemic. Coghlan, Andy; MacKenzie, Debora // New Scientist;7/23/2011, Vol. 211 Issue 2822, p6 

    The article discusses antiretroviral drugs (ARVs), drugs which may be able to help people who have been infected with HIV live longer and prevent people from being infected with the disease. Two studies presented at an HIV and AIDS conference in Rome, Italy showed that pre-exposure prophylaxis...

  • HIV/AIDS IN EASTERN EUROPE: MORE THAN A SEXUAL HEALTH CRISIS. Lazarus, Jeffrey V.; Bollerup, Annemarie; Srdan Matić, Srdan // Central European Journal of Public Health;2006, Vol. 14 Issue 2, p55 

    HIV/AIDS is often described as a sexually transmitted disease. In the former USSR, however, the HIV/AIDS epidemic is being driven by injecting drug use among men. This article addresses several widely circulated assumptions about HIV in eastern Europe: that sexual contact is the primary mode of...

  • Suministro de antirretrovirales en Argentina: Programa Nacional de Lucha contra los Retrovirus del Humano, SIDA y ETS. Colautti, Marisel; Luppi, Irene; Salamano, Mercedes; Traverso, María Luz; Botta, Carina; Palchik, Valeria // Revista Panamericana de Salud Publica;Jan2009, Vol. 25 Issue 1, p62 

    Objectives. To evaluate the supply cycle of antiretroviral (ARV) drugs, overseen by the National Program to Combat Human Retroviruses, AIDS, and STDs, through its order fulfillment indicators, and to obtain input from supply chain stakeholders. Methods. A study was carried out from...

  • The Treatment of Patients With HIV. Vogel, M.; Schwarze-Zander, C.; Wasmuth, J.; Spengler, U.; Sauerbruch, T.; Rockstroh, J. K. // Deutsches Aerzteblatt International;7/19/2010, Vol. 107 Issue 28/29, p507 

    Background: Infection with the human immunodeficiency virus (HIV) remains a major medical challenge. Methods: Selective literature review, including the current German/Austrian, European, and American guidelines on the treatment of HIV infection in adults. Results: In Germany, 3000 persons...

  • Clinical Profile of Neurological Manifestation in Human Immunodeficiency Virus-positive Patients. Sonkar, Satyendra K.; Gupta, Abhinav; Atam, Virendra; Chaudhary, Shyam C.; Tripathi, Anil K.; Sonkar, Gyanendra K. // North American Journal of Medical Sciences;Nov2012, Vol. 4 Issue 11, p596 

    The article presents a study that determines the neurological clinical profile of patients with human immunodeficiency virus (HIV). It states that the study was conducted at the Gandhi ward of the Department of Medicine of King George's Medical University in Lucknow, India. It also notes that...

  • How HIV Treatment Failure Occurs Without Resistance. Breindl, Anette // BioWorld Today;9/5/2012, Vol. 23 Issue 172, p1 

    The article reports on a mathematical model developed by scientists which may be able to help determine the best way to prevent resistance to currently available HIV drugs and identify effective combinations of new drugs early on in clinical development. According to Alison Hill of Harvard...

  • Evolutionary pathways of transmitted drug-resistant HIV-1. Pingen, Marieke; Nijhuis, Monique; de Bruijn, Johan A.; Boucher, Charles A. B.; Wensing, Annemarie M. J. // Journal of Antimicrobial Chemotherapy (JAC);Jul2011, Vol. 66 Issue 7, p1467 

    Several large studies in Europe and the USA revealed that approximately 10% of all newly diagnosed patients harbour HIV-1 variants with at least one major resistance-associated mutation. In this review we discuss the underlying mechanisms that drive the evolution of drug-resistant viruses after...

  • Pyrosequencing Dried Blood Spots Reveals Differences in HIV Drug Resistance between Treatment Naïve and Experienced Patients. Ji, Hezhao; Li, Yang; Liang, Binhua; Pilon, Richard; MacPherson, Paul; Bergeron, Michèle; Kim, John; Graham, Morag; Van Domselaar, Gary; Sandstrom, Paul; Brooks, James // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Dried blood spots (DBS) are an alternative specimen collection format for HIV-1 genotyping. DBS produce HIV genotyping results that are robust and equivalent to plasma when using conventional sequencing methods. However, using tagged, pooled pyrosequencing, we demonstrate that concordance...

  • HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Vahabpour, Rouhollah; Bokharaei-Salim, Farah; Kalantari, Saeed; Garshasbi, Saba; Monavari, Seyed; Esghaei, Maryam; Memarnejadian, Arash; Fakhim, Atousa; Keyvani, Hossein // Archives of Virology;Jun2017, Vol. 162 Issue 6, p1477 

    In recent years, the patterns of human immunodeficiency virus 1 (HIV-1) transmission in Iran have been changing gradually from drug injection to unprotected sexual contact. This study sought to investigate the phylogenetic trends and characteristics of transmitted drug resistance (TDR) mutations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics